

중추신경계 염증성 탈수초성 질환의 최신지견







김 수 현

국립암센터 신경과


Demyelinating disease

Su-Hyun Kim, MD, PhD


Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea



Cladribine mechanism of action




Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis



Neurology 2020;94:e2457-67


Plasma NFL levels at early stages of MS may serve as a prognostic tool to assess the risk of developing permanent disability in MS



Neurology 2020;94:e2457-67

NeuroMyelitis Optica Spectrum Disorder (NMOSD)

FDA approved drugs for NMOSD





Randomized clinical trials for NMOSD

| Clinical Trial Name | N | Drug Name | Drug target | Trial status | Primary endpoint | Reduction in attack risk |
|---------------------------|-----------------------|---------------------------|---------------|-------------------------------|-----------------------|--------------------------|
| PREVENT NCT01892345 | AQP4+ only 143 | Eculizumab | C5 Protein | Phase III (mainly add-on) | Time to first relapse | 84% |
| N-Momentum NCT02206770 | AQP4+/- 212+18+230 | Inebilizumab (MED-551) | CD19+ B cells | Phase II/III (Monotherapy) | Time to first relapse | 73% (AQP4+ 77%) |
| SAkura Sky NCT02073279 | AQP4+/- 54+31+55 | Satralizumab (SA237) | IL-6 receptor | Phase III (monotherapy) | Time to first relapse | 55% (AQP4+ 74%) |
| SAkura Sky NCT02026664 | AQP4+/- 55+28+83 | Satralizumab (SA237) | IL-6 receptor | Phase III (Add-on) | Time to first relapse | 65% (AQP4+ 78%) |

N Engl J med 2019;381:614-625/ Lancet 2019;394:1352-1363/ N Engl J Med 2019;381:2114-2124/ Lancet Neurol 2020;19:402-412

Myelin Oligodendrocyte Glycoprotein (MOG)-Ab associated disease



Treatment of MOG-Ab disease

- MS DMT seemed ineffective for patients with MOG-Ab
- Maintenance steroid therapy can play an important role in reducing relapse rate.
- AZA or MMF might reduce the relapse risk in patients with MOG-Ab.
- Rituximab might reduce the relapse risk in patients with MOG-Ab. But compared to studies in NMOSD, the efficacy seems lower in patients with MOG-Ab. Some patients relapsed despite apparent circulating B-cell depletion.
- IVIG might reduce the relapse rate in adults patients with MOG-Ab, but the efficacy might not be as good as for paediatric patients.
- Tocilizumab might play an important role in preventing relapses in the refractory patients.

Mult Scler relat Disord 2020;44:102251/ Ann Neurol 2020;87(2):256-266